相关实验视频

Updated: Jan 10, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

拉布10在病理性心脏缩的发展中起着保护作用

Fang Xu¹, Min Wu¹, Yihan Wang¹

¹Department of Genetics, National Research Institute for Family Planning, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100081, China.

Journal of molecular and cellular cardiology plus

|November 28, 2025

概括

Rab10是一种新型调节剂,通过抑制关键信号通路来抑制心脏缩. 降低Rab10的调节会使心力衰竭恶化,这表明它对心脏缩的治疗潜力.

科学领域:

心血管生物学心血管生物学
分子心脏病学分子心脏病学
细胞信号传输细胞信号传输

背景情况:

长期的心脏缩是心力衰竭 (HF) 的重要危险因素.
拉布GTPases调节蛋白质的贩运,对于细胞在缩期间重塑至关重要.
拉布10在心脏缩中的特定作用在很大程度上仍未被探索.

研究的目的:

为了确定心脏缩的新型调节者.
研究Rab10在心脏缩的发展和进展中的作用.
探索Rab10在心脏缩中的治疗潜力.

主要方法:

使用Ang II或压力过载在新生小鼠心肌细胞 (NRCMs) 和小鼠模型中诱导心肌细胞缩.
在高形条件下评估Rab10表达水平.
在体外和体内 (心脏特异性转基因小鼠和AAV9-介导的敲击) 操纵Rab10水平 (过度表达和敲击).
评估心脏功能和多变性心脏重塑.
涉及ERK1/2和AKT酸化和miR-199a调节的机制研究.

主要成果:

Rab10表达在响应多变性刺激时显著下调.
在体外和体外,Rab10过度表达减弱了心脏缩,改善了心脏功能.
拉布10敲击加剧的压力过载引起的心脏缩.
Rab10抑制了ERK1/2和AKT酸化,这是高的关键途径.
Rab10在转录后被miR-199a降低调节.

结论:

拉布10作为一种新的内源性心脏缩抑制剂.
拉布10缺乏会加剧心脏缩,突出其保护作用.
Rab10代表了治疗致病性心脏缩和预防心力衰竭的潜在治疗标.

关键词:

在英格兰,英格兰 II.心脏过度缩小的心脏过度缩小拉布10 拉布10 拉布10 在TACTAC中,我们只能捕鱼.在1991年1月1日,他与米尔·布莱克·布莱克·布莱克·布莱克·布莱克·布莱克·布莱克·布莱克.

更多相关视频

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes

Published on: September 24, 2013

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

相关概念视频

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...